Spinal muscular atrophy, type III
MONDO:0009672Proximal spinal muscular atrophy type 3 (SMA3) is a relatively mild form of proximal spinal muscular atrophy characterized by muscle weakness and hypotonia resulting from the degeneration and loss of the lower motor neurons in the spinal cord and the brain stem nuclei.
Also known as: childhood spinal muscular atrophy, juvenile spinal muscular atrophy, Kugelberg Welander Syndrome, Kugelberg-Welander disease, SMA type 3, SMA type III, SMA-III, SMA3
28 clinical trials for this condition and its sub-types, 13 tagged with Spinal muscular atrophy, type III itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New Muscle-Boosting drug shows promise for SMA patients in major trial
Disease control CompletedThis Phase 3 trial tested apitegromab, a drug that blocks a muscle-limiting protein, in 188 nonambulatory children and young adults with later-onset spinal muscular atrophy (SMA types 2 and 3). All participants were already taking standard SMA therapies (nusinersen or risdiplam).…
Phase 3 • Sponsor: Scholar Rock, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New fabric brace could give arm strength back to patients with muscle diseases
Symptom relief CompletedThis study tests a special fabric shoulder brace designed to mimic muscle support for people with neuromuscular disorders like muscular dystrophy, SMA, and ALS. About 30 participants will wear the brace and perform arm tasks to see if it improves movement, strength, and daily fun…
Sponsor: Seoul National University Hospital • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New drug shows promise for improving walking in adults with spinal muscular atrophy
Symptom relief CompletedThis study tested an experimental drug called NMD670 in 52 adults with type 3 spinal muscular atrophy who can still walk. The goal was to see if the drug helps them walk farther in 6 minutes and improves muscle strength compared to a placebo. The trial is now complete, and result…
Phase 2 • Sponsor: NMD Pharma A/S • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Spinal zap trial aims to help SMA patients move better
Symptom relief CompletedThis small pilot study tested whether a temporary spinal cord stimulator (like a pacemaker for the spine) could help people with spinal muscular atrophy types 3 and 4 move their legs better. Three adults who could stand independently received the implant for up to 29 days. The go…
Sponsor: Marco Capogrosso • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
New tests could reveal how SMA progresses in adults
Knowledge-focused CompletedThis study looked at 67 adults with spinal muscular atrophy (SMA) types 2 and 3 to see if special electrical tests (MUNE and CMAP) can track nerve loss over time. The goal was to find better ways to measure how the disease changes, not to test a treatment. Participants had geneti…
Sponsor: Ohio State University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Braces and SMA: new insights on sitting, standing, and walking
Knowledge-focused CompletedThis study looked back at 80 children with spinal muscular atrophy (SMA) types II and III to see how using braces (orthoses) helped them sit, stand, and walk. Researchers recorded when and how often children achieved these milestones and what types of braces they used. The goal w…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC